NYSE:BHC - Bausch Health Companies Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $15.67
Forecasted Upside: 83.67 %
Number of Analysts: 6
Breakdown:
0 Sell Ratings
1 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$8.53 As of 07/1/2022 04:59 PM ET

▲ +0.17 (2.03%)

1 month | 3 months | 12 months

Get New Bausch Health Companies Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHC

^$15.67

▲ +83.67% Upside Potential

This price target is based on 6 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is $15.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 83.67% upside from the last price of $8.53.

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Bausch Health Companies. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

1/10/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

7/9/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

10/7/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

1/5/2022

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/5/2022

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/4/2022

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/4/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/13/2022	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$12.00	High
5/26/2022	Piper Sandler	Lower Price Target		$27.00 ➝ $7.00	Low
5/15/2022	Royal Bank of Canada	Lower Price Target	Outperform	$21.00 ➝ $17.00	Low
5/11/2022	BMO Capital Markets	Lower Price Target		$26.00 ➝ $15.00	High
5/11/2022	Bank of America	Lower Price Target		$25.00 ➝ $12.00	High
5/9/2022	Royal Bank of Canada	Lower Price Target	Outperform	$32.00 ➝ $21.00	High
2/1/2022	Royal Bank of Canada	Lower Price Target	Outperform	$40.00 ➝ $34.00	Low
11/8/2021	BMO Capital Markets	Reiterated Rating	Hold		Low
11/3/2021	Royal Bank of Canada	Lower Price Target	Outperform	$41.00 ➝ $40.00	High
10/1/2021	Jefferies Financial Group	Reiterated Rating	Buy		High
8/4/2021	Barclays	Lower Price Target	In-Line ➝ Overweight	$35.00 ➝ $31.00	High
7/8/2021	HC Wainwright	Reiterated Rating	Buy		Low
5/5/2021	Royal Bank of Canada	Lower Price Target	Outperform	$42.00 ➝ $41.00	Low
3/30/2021	Bank of America	Reiterated Rating	Neutral ➝ Underperform	$27.00	Low
3/24/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$27.00	Low
3/16/2021	HC Wainwright	Boost Price Target	Buy	$50.00 ➝ $55.00	Low
3/14/2021	JPMorgan Chase & Co.	Reiterated Rating	Buy	$38.00	Low
3/2/2021	Citigroup	Boost Price Target		$32.00 ➝ $37.00	Low
2/26/2021	Morgan Stanley	Boost Price Target	Equal Weight	$22.00 ➝ $35.00	Medium
2/25/2021	Barclays	Boost Price Target	Overweight	$27.00 ➝ $35.00	Low
2/17/2021	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$26.00 ➝ $42.00	Low
2/16/2021	JPMorgan Chase & Co.	Boost Price Target	Overweight	$32.00 ➝ $38.00	Low
1/22/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$25.00 ➝ $30.00	Low
1/15/2021	Jefferies Financial Group	Boost Price Target		$27.00 ➝ $33.00	Low
11/5/2020	Piper Sandler	Lower Price Target	Overweight	$26.00 ➝ $25.00	Low
10/28/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$18.00 ➝ $17.00	Medium
10/26/2020	Barclays	Boost Price Target	Overweight	$28.00 ➝ $29.00	High
9/17/2020	Bank of America	Upgrade	Underperform ➝ Neutral	$19.00	High
8/24/2020	HC Wainwright	Reiterated Rating	Buy	$64.00 ➝ $50.00	High
8/19/2020	Piper Sandler	Lower Price Target	Overweight	$32.00 ➝ $26.00	High
8/10/2020	Royal Bank of Canada	Boost Price Target	Sector Perform	$23.00 ➝ $26.00	Low
8/10/2020	Citigroup	Lower Price Target	Buy	$27.00 ➝ $26.00	Medium
8/7/2020	Barclays	Boost Price Target	Overweight	$25.00 ➝ $28.00	High
7/31/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$24.00 ➝ $23.00	Low
7/7/2020	Bank of America	Boost Price Target	Underperform	$12.00 ➝ $14.00	High
6/17/2020	HC Wainwright	Boost Price Target	Buy	$50.00 ➝ $64.00	Medium
5/8/2020	Cfra	Lower Price Target	Hold	$28.00 ➝ $18.00	Low
5/8/2020	SunTrust Banks	Lower Price Target	Buy	$25.00 ➝ $24.00	High
5/8/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$25.00 ➝ $24.00	High
4/30/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$17.00 ➝ $18.00	Low
4/28/2020	HC Wainwright	Reiterated Rating	Buy	$50.00	Medium
4/28/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$26.00 ➝ $25.00	High
4/24/2020	Citigroup	Initiated Coverage	Buy	$30.00	High
4/23/2020	Jefferies Financial Group	Lower Price Target	Buy	$35.00 ➝ $27.00	Medium
4/2/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low
3/23/2020	HC Wainwright	Lower Price Target	Buy	$60.00 ➝ $50.00	High
3/23/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$32.00 ➝ $17.00	High
3/17/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$31.00 ➝ $26.00	Medium
2/20/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$33.00 ➝ $31.00	High
2/20/2020	SunTrust Banks	Lower Price Target	Buy	$32.00 ➝ $31.00	Low
2/19/2020	Cowen	Reiterated Rating	Buy	$40.00	Low
2/19/2020	Guggenheim	Reiterated Rating	Buy	$36.00	Low
2/11/2020	Morgan Stanley	Lower Price Target	Overweight	$34.00 ➝ $32.00	Low
2/4/2020	Royal Bank of Canada	Boost Price Target	Sector Perform	$31.00 ➝ $33.00	High
1/29/2020	Wolfe Research	Downgrade	Outperform ➝ Peer Perform		Low
1/26/2020	Barclays	Reiterated Rating	Buy	$33.00	Low
1/22/2020	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$32.00	Medium
12/30/2019	Piper Jaffray Companies	Boost Price Target	Neutral ➝ Overweight	$30.00 ➝ $39.00	Medium
12/23/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	N/A
12/12/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$32.00 ➝ $38.00	High
12/2/2019	HC Wainwright	Reiterated Rating	Buy	$54.00 ➝ $60.00	Low
12/2/2019	The Goldman Sachs Group	Initiated Coverage	Neutral	$30.00	Low
11/5/2019	Barclays	Boost Price Target	Overweight	$28.00 ➝ $30.00	Low
10/25/2019	Cowen	Initiated Coverage	Outperform	$35.00	Medium
9/17/2019	Wells Fargo & Company	Reiterated Rating	Sell		Low
9/12/2019	Guggenheim	Initiated Coverage	Buy	$30.00	High
8/15/2019	TD Securities	Upgrade	Hold ➝ Buy	$28.00	Medium
8/7/2019	HC Wainwright	Boost Price Target	Market Perform ➝ Buy	$50.00 ➝ $54.00	Low
7/29/2019	HC Wainwright	Lower Price Target	Buy	$58.00 ➝ $50.00	Low
7/19/2019	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform	$31.00	Low
7/15/2019	Wells Fargo & Company	Reiterated Rating	Sell		Low
7/8/2019	Barclays	Set Price Target	Buy	$28.00	Low
6/20/2019	Mizuho	Set Price Target	Buy	$45.00	Medium
6/11/2019	Piper Jaffray Companies	Set Price Target	Buy	$29.00	Medium
6/11/2019	Barclays	Reiterated Rating	Overweight ➝ Overweight	$28.00	Medium
5/31/2019	Cantor Fitzgerald	Set Price Target	Buy	$32.00	Low
5/17/2019	Wells Fargo & Company	Set Price Target	Sell	$9.00	Low
5/13/2019	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$24.80	Low
5/7/2019	Mizuho	Boost Price Target	Buy	$41.00 ➝ $45.00	Low
4/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	Low
4/2/2019	Piper Jaffray Companies	Set Price Target	Buy	$28.00	Low
3/20/2019	Bank of America	Reiterated Rating	Underperform	$18.00	High
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$30.00	High
3/18/2019	Mizuho	Boost Price Target	Buy	$39.00 ➝ $41.00	High
2/28/2019	HC Wainwright	Reiterated Rating	Buy		Medium
2/19/2019	Wells Fargo & Company	Boost Price Target	Sell ➝ Underperform	$9.00 ➝ $25.19	High
1/6/2019	Mizuho	Reiterated Rating	Buy	$39.00	High
1/2/2019	UBS Group	Upgrade	Buy		High
1/1/2019	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$27.00	High
12/17/2018	Morgan Stanley	Set Price Target	Buy	$32.00	High
12/14/2018	HC Wainwright	Upgrade	Average ➝ Buy		Low
12/12/2018	Wells Fargo & Company	Set Price Target	Sell	$9.00	Medium
11/30/2018	Mizuho	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $38.00	Low
11/13/2018	BMO Capital Markets	Reiterated Rating	Hold	$26.00	Medium
11/7/2018	TD Securities	Boost Price Target	Hold	$24.00 ➝ $28.00	Low
11/7/2018	Royal Bank of Canada	Boost Price Target	Hold	$30.00 ➝ $31.00	Medium
11/6/2018	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
11/5/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$32.00	High
10/15/2018	HC Wainwright	Set Price Target	Hold	$25.00	Low
10/8/2018	HC Wainwright	Set Price Target	Hold	$25.00	Medium
10/8/2018	Mizuho	Reiterated Rating	Buy	$35.00	Medium
10/8/2018	Royal Bank of Canada	Set Price Target	Sector Perform ➝ Hold	$26.00 ➝ $30.00	Medium
9/13/2018	HC Wainwright	Reiterated Rating	Hold	$25.00	High
9/13/2018	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$16.00 ➝ $19.00	High
9/12/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$30.00	High
9/12/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	High
8/31/2018	HC Wainwright	Reiterated Rating	Hold	$20.00	Medium
8/13/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$20.00 ➝ $22.00	Medium
8/8/2018	Royal Bank of Canada	Boost Price Target	Hold	$25.00 ➝ $26.00	Low
8/8/2018	JPMorgan Chase & Co.	Boost Price Target	Underweight	$18.00	Low
8/7/2018	Piper Jaffray Companies	Set Price Target	Sell	$16.00	Low
8/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	Low
8/7/2018	Mizuho	Reiterated Rating	Buy	$31.00	High
8/6/2018	Wells Fargo & Company	Reiterated Rating	Sell		High
7/23/2018	Piper Jaffray Companies	Set Price Target	Sell	$13.00	Low
6/29/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		Low
6/29/2018	Mizuho	Reiterated Rating	Buy	$31.00	Medium
6/22/2018	TD Securities	Downgrade	Buy ➝ Hold	$24.00	Low
6/20/2018	HC Wainwright	Reiterated Rating	Hold	$20.00	Low
6/6/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$20.00 ➝ $34.00	High
6/5/2018	HC Wainwright	Set Price Target	Hold	$20.00	High
6/1/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$25.00	Low
5/15/2018	Mizuho	Upgrade	Neutral ➝ Buy		Low
5/14/2018	Cantor Fitzgerald	Set Price Target	Buy	$25.00	Low
5/11/2018	BMO Capital Markets	Boost Price Target	Market Perform	$17.00 ➝ $20.00	Low
5/9/2018	BTIG Research	Reiterated Rating	Hold		Low
5/9/2018	Jefferies Financial Group	Boost Price Target	Buy	$23.00	Low
5/9/2018	TD Securities	Boost Price Target	Buy	$23.00 ➝ $24.00	Low
5/9/2018	Royal Bank of Canada	Boost Price Target	Sector Perform	$18.00 ➝ $19.00	Low
5/9/2018	JPMorgan Chase & Co.	Set Price Target	Sell	$13.00	High
5/9/2018	Piper Jaffray Companies	Set Price Target	Sell	$13.00	Low
5/8/2018	The Goldman Sachs Group	Set Price Target	Sell	$16.00	Medium
5/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$25.00	High
5/7/2018	HC Wainwright	Reiterated Rating	Positive ➝ Hold	$16.00	Medium
5/2/2018	Royal Bank of Canada	Set Price Target	Hold	$18.00	Medium
4/30/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$20.00 ➝ $22.00	Low
4/6/2018	Mizuho	Upgrade	Underperform ➝ Neutral	$10.00 ➝ $15.00	High
3/21/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$20.00	Medium
3/20/2018	Wells Fargo & Company	Reiterated Rating	Sell		Medium
3/15/2018	HC Wainwright	Reiterated Rating	Hold	$16.00	Medium
3/12/2018	Wells Fargo & Company	Reiterated Rating	Sell		Low
3/5/2018	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$18.00	Low
3/1/2018	TD Securities	Lower Price Target	Buy	$27.00 ➝ $23.00	Low
3/1/2018	Piper Jaffray Companies	Reiterated Rating	Sell	$12.00 ➝ $10.00	High
2/28/2018	Cfra	Downgrade	Hold		High
2/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$25.00	Medium
2/28/2018	Wells Fargo & Company	Reiterated Rating	Sell		Medium
2/26/2018	HC Wainwright	Reiterated Rating	Neutral	$18.00	Low
2/21/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$20.00	Low
1/24/2018	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Sell	$18.00	High
1/19/2018	Cantor Fitzgerald	Set Price Target	Buy	$25.00	Medium
1/16/2018	Wells Fargo & Company	Reiterated Rating	Sell	$9.00	Low
1/16/2018	HC Wainwright	Boost Price Target	Buy	$17.00 ➝ $24.00	High
1/16/2018	HC Wainwright	Set Price Target	Hold	$17.00 ➝ $24.00	High
1/5/2018	TD Securities	Boost Price Target	Buy	$20.00 ➝ $27.00	High
1/4/2018	Wells Fargo & Company	Reiterated Rating	Sell		Low
1/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$25.00	High
12/26/2017	Cantor Fitzgerald	Set Price Target	Buy	$25.00	Low
12/15/2017	Mizuho	Boost Price Target	Underperform ➝ Underperform	$7.00 ➝ $10.00	Medium
12/14/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$12.00	High
12/3/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$18.00	Low
11/16/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$19.00 ➝ $18.00	N/A
11/13/2017	Wells Fargo & Company	Reiterated Rating	Sell		N/A
11/13/2017	BMO Capital Markets	Boost Price Target	Market Perform	$16.00 ➝ $17.00	N/A
11/10/2017	Piper Jaffray Companies	Reiterated Rating	Sell	$12.00	N/A
11/9/2017	HC Wainwright	Reiterated Rating	Hold	$17.00	N/A
11/8/2017	Royal Bank of Canada	Set Price Target	Sector Perform	$18.00	N/A
11/8/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$19.00	N/A
11/7/2017	TD Securities	Upgrade	Hold ➝ Buy	$20.00	N/A
11/3/2017	TD Securities	Upgrade	Hold ➝ Buy	$20.00	N/A
11/3/2017	HC Wainwright	Reiterated Rating	Hold	$17.00	N/A
10/31/2017	Cantor Fitzgerald	Set Price Target	Buy	$23.00	N/A
10/30/2017	BMO Capital Markets	Reiterated Rating	Hold	$16.00	N/A
10/27/2017	Wells Fargo & Company	Reiterated Rating	Sell		N/A
10/22/2017	Piper Jaffray Companies	Set Price Target	Sell	$14.00	N/A
10/20/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$21.00 ➝ $18.00	N/A
10/9/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$18.00	N/A
10/4/2017	HC Wainwright	Reiterated Rating	Hold	$17.00	Low
9/30/2017	Wells Fargo & Company	Reiterated Rating	Underperform	$8.00	High
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$23.00	Low
9/25/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$19.00	Low
9/18/2017	HC Wainwright	Reiterated Rating	Hold	$17.00	Low
9/17/2017	Piper Jaffray Companies	Reiterated Rating	Sell	$14.00	Low
8/29/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$23.00	Low
8/29/2017	Mizuho	Reiterated Rating	Sell	$8.00 ➝ $7.00	High
8/21/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$19.00	High
8/21/2017	Stifel Nicolaus	Reiterated Rating	Buy	$45.00	Medium
8/21/2017	HC Wainwright	Set Price Target	Hold	$17.00	Low
8/16/2017	Cantor Fitzgerald	Set Price Target	Buy	$23.00	Low
8/10/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$16.00	Low
8/10/2017	Rodman & Renshaw	Reiterated Rating	Neutral	$17.00	High
8/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$18.00	High
8/10/2017	Stifel Nicolaus	Reiterated Rating	Buy	$35.00	Medium
8/10/2017	Wells Fargo & Company	Reiterated Rating	Underperform	$9.00	Medium
8/9/2017	Mizuho	Reiterated Rating	Underperform	$8.00	Medium
8/9/2017	Scotiabank	Boost Price Target	Sector Perform	$14.00 ➝ $16.00	Medium
8/9/2017	HC Wainwright	Set Price Target	Hold	$17.00	High
8/9/2017	Piper Jaffray Companies	Set Price Target	Sell	$14.00	High
8/3/2017	Royal Bank of Canada	Boost Price Target	Sector Perform ➝ Sector Perform	$19.00 ➝ $21.00	High
7/30/2017	Wells Fargo & Company	Dropped Coverage	Sell	$9.00	High
7/28/2017	Cantor Fitzgerald	Set Price Target	Buy	$23.00	Low
7/27/2017	BMO Capital Markets	Reiterated Rating	Hold	$15.00	High
7/17/2017	JPMorgan Chase & Co.	Set Price Target	Hold	$10.00	Low
7/17/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$18.00 ➝ $19.00	High
7/17/2017	Stifel Nicolaus	Reiterated Rating	Buy	$35.00	Low
7/14/2017	Jefferies Financial Group	Reiterated Rating	Buy	$18.00	Low
7/14/2017	Wells Fargo & Company	Reiterated Rating	Sell		Low
7/14/2017	Piper Jaffray Companies	Reiterated Rating	Underweight	$10.00	High
7/12/2017	TD Securities	Boost Price Target	Hold	$15.00 ➝ $20.00	Low
7/6/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$10.00	Low

(Data available from 7/5/2017 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

4 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/7/2021

2 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/6/2022

8 very positive mentions
12 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/5/2022

2 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/7/2022

1 very positive mentions
4 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

4/6/2022

5 very positive mentions
9 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

5/6/2022

3 very positive mentions
7 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

6/5/2022

4 very positive mentions
15 positive mentions
1 negative mentions
3 very negative mentions

Mentions as of

7/5/2022

Current Sentiment

Recent Stories by Sentiment

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $8.53

$8.03

$8.54

50 Day Range

MA: $10.81

$7.06

$20.56

52 Week Range

Now: $8.53

$6.88

$30.30

Volume

252,264 shs

Average Volume

5,811,302 shs

Market Capitalization

$3.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?: The following Wall Street analysts have issued research reports on Bausch Health Companies in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, StockNews.com, and TheStreet.
View the latest analyst ratings for BHC.
What is the current price target for Bausch Health Companies?: 0 Wall Street analysts have set twelve-month price targets for Bausch Health Companies in the last year. Their average twelve-month price target is $15.67, suggesting a possible upside of 83.7%.
View the latest price targets for BHC.
What is the current consensus analyst rating for Bausch Health Companies?: Bausch Health Companies currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHC will outperform the market and that investors should add to their positions of Bausch Health Companies.
View the latest ratings for BHC.
What other companies compete with Bausch Health Companies?: Other companies that are similar to Bausch Health Companies include United Therapeutics, Biohaven Pharmaceutical, Jazz Pharmaceuticals, Elanco Animal Health, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Organon & Co., Legend Biotech, Grifols, Maravai LifeSciences, Sarepta Therapeutics, Perrigo, Ionis Pharmaceuticals, Ascendis Pharma A/S and Intra-Cellular Therapies. Learn More about companies similar to Bausch Health Companies.
How do I contact Bausch Health Companies' investor relations team?: Bausch Health Companies' physical mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company's listed phone number is (514) 744-6792 and its investor relations email address is [email protected] The official website for Bausch Health Companies is www.bauschhealth.com. Learn More about contacing Bausch Health Companies investor relations.

NYSE:BHC - Bausch Health Companies Stock Price Target and Predictions

Analyst Price Target for BHC

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.20 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?

What is the current price target for Bausch Health Companies?

What is the current consensus analyst rating for Bausch Health Companies?

What other companies compete with Bausch Health Companies?

How do I contact Bausch Health Companies' investor relations team?